Treatment of DCIS Needs to Consider Patient Age and Tumor

Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

CHICAGO--Despite an overall trend toward breast conservation, many breast cancer authorities believe that ductal carcinoma in situ (DCIS) too often is treated by mastectomy, and that axillary dissection and irradiation frequently are performed unnecessarily.

CHICAGO--Despite an overall trend toward breast conservation, many breastcancer authorities believe that ductal carcinoma in situ (DCIS) too oftenis treated by mastectomy, and that axillary dissection and irradiationfrequently are performed unnecessarily.

In order to make the "punishment fit the crime," physicianstreating DCIS need to balance the extent of surgery and the applicationof irradiation with a number of factors, William Wood, MD, said at the50th Cancer Symposium of the Society for Surgical Oncology. These includenot only tumor size and margins, but also tumor grade and the patient'sage.

Since DCIS can develop into invasive disease, "we can't take ittoo lightly," said Dr. Wood, professor and chairman of the Departmentof Surgery, Emory University School of Medicine. However, he said, a formaltreatment algorithm for DCIS "requires thoughtful application basedupon the number of years a woman would be at risk, the likely biology ofthe tumor, and its extent."

The algorithm presented by Dr. Wood involves surgical excision of theDCIS with a relatively small resection margin for biopsy; magnificationview mammog-raphy to make sure there is no stream of DCIS moving towardthe nipple or areola or going off elsewhere in the breast; and detailedpathologic evaluation.

DCIS that has a 1- to 4-mm focus and 5- to 10-mm margin would be observedafter excision, according to this algorithm. "I would do nothing else;I think any additional treatment is likely to be overtreatment," Dr.Wood said.

For DCIS with a 5- to 20-mm focus and 5-mm to 10-mm margin, Dr. Woodwould add irradiation. Lumpectomy and radiation therapy would also be appropriatefor more than 20 mm of tumor as long as a 10-mm clear margin could be obtainedand the breast could be preserved in appearance.

The algorithm calls for more extensive treatment of a comedo or high-gradetumor, particularly in a young patient. Less extensive treatment wouldbe indicated "in an older patient where a low-grade disease mightnever become an event in her lifetime," he said.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content